The Efficacy of Neutral Position Beractant Administration in Neonates

Abstract

Objective The objective was to compare the efficacy and adverse effects of beractant administration in neonates via a single aliquot in a neutral position versus positioning the neonates on their left then right side and two aliquots administration.

Study Design This was a retrospective cohort chart review of neonates who were diagnosed with respiratory distress syndrome and received beractant during two 15-month periods between 2013 and 2015 and 2015 and 2016 to compare the change in the fraction of inspired oxygen (FiO₂) 1 hour after beractant administration.

Results There were no differences in FiO₂ 1 hour after beractant between groups (p = 0.617). Adverse events and other comorbidities did not differ between the groups.

Conclusion Changing administration of beractant from two aliquots and positions to a neutral position resulted in no significant change in FiO₂ and may be considered as an option for administration in neonates.

Keywords

neonate - beractant - surfactant - administration - outcome - safety

• References

• 1 Nkadi PO, Merritt TA, Pillers DA. An overview of pulmonary surfactant in the neonate: genetics, metabolism, and the role of surfactant in health and disease. Mol Genet Metab 2009; 97 (02) 95-101
• 2 Suresh GK, Soll RF. Overview of surfactant replacement trials. J Perinatol 2005; 25 (Suppl. 02) S40-S44
• 3 Reuter S, Moser C, Baack M. Respiratory distress in the newborn. Pediatr Rev 2014; 35 (10) 417-428
• 4 Polin RA, Carlo WA. ; Committee on Fetus and Newborn; American Academy of Pediatrics. Surfactant replacement therapy for preterm and term neonates with respiratory distress. Pediatrics 2014; 133 (01) 156-163
• 5 Pramanik AK, Rangaswamy N, Gates T. Neonatal respiratory distress: a practical approach to its diagnosis and management. Pediatr Clin North Am 2015; 62 (02) 453-469
• 6 Olmeda B, Villén L, Cruz A, Orellana G, Perez-Gil J. Pulmonary surfactant layers accelerate O(2) diffusion through the air-water interface. Biochim Biophys Acta 2010; 1798 (06) 1281-1284
• 7 Survanta® (beractant) [package insert]. North Chicago, IL: AbbVie Inc; 2012
• 8 Duong HH, Mirea L, Shah PS, Yang J, Lee SK, Sankaran K. Pneumothorax in neonates: trends, predictors and outcomes. J Neonatal Perinatal Med 2014; 7 (01) 29-38
• 9 Raju TN, Langenberg P. Pulmonary hemorrhage and exogenous surfactant therapy: a metaanalysis. J Pediatr 1993; 123 (04) 603-610
• 10 Curosurf® (poractant alfa) [package insert]. Cary, NC: Chiesi USA Inc; 2014
• 11 INFASURF® (calfactant) [package insert]. Amherst, NY: ONY Inc; 2011
• 12 Davis JM, Russ GA, Metlay L, Dickerson B, Greenspan BS. Short-term distribution kinetics of intratracheally administered exogenous lung surfactant. Pediatr Res 1992; 31 (05) 445-450
• 13 Karadag A, Ozdemir R, Degirmencioglu H. , et al. Comparison of three different administration positions for intratracheal beractant in preterm newborns with respiratory distress syndrome. Pediatr Neonatol 2016; 57 (02) 105-112